Government-Owned Inventions; Availability for Licensing, 23272-23274 [2010-10264]
Download as PDF
<![CDATA[
23272
Federal Register / Vol. 75, No. 84 / Monday, May 3, 2010 / Notices
EXHIBIT 1—ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
responding
organization
Number of
organizations
Form name
Hours per
response
Total burden
hours
Semi-structured interviews ..............................................................
Cognitive interviews .........................................................................
9
30
1
1
1
1
9
30
Total ..........................................................................................
39
NA
NA
39
EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN
Number of
respondents
Form name
Total burden
hours
Average hourly
wage rate *
Total cost burden
Semi-structured interviews ..............................................................
Cognitive interviews .........................................................................
9
30
9
30
$42.67
42.67
$384
1,280
Total ..........................................................................................
39
39
NA
1,664
* Based upon the mean of the average wages, National Compensation Survey: Occupational wages in the United States 2008, ‘‘U.S. Department of Labor, Bureau of Labor Statistics.’’
Estimated Annual Costs to the Federal
Government
government to conduct this redesign of
the Adverse Event Reporting
Questionnaire and associated sample
design. Since this project will last for
Exhibit 3 shows the estimated total
and annualized cost to the Federal
one year the total and annualized costs
are the same. The total cost is estimated
to be $120,000.
EXHIBIT 3—ESTIMATED TOTAL AND ANNUALIZED COST
Cost component
Total cost
Annualized cost
$24,000
46,000
26,000
24,000
$24,000
46,000
26,000
24,000
Total ..........................................................................................................................................................
erowe on DSK5CLS3C1PROD with NOTICES
Project Development .......................................................................................................................................
Data Collection Activities .................................................................................................................................
Data Processing and Analysis .........................................................................................................................
Project Management ........................................................................................................................................
120,000
120,000
Request for Comments
In accordance with the above-cited
Paperwork Reduction Act legislation,
comments on AHRQ’s information
collection are requested with regard to
any of the following: (a) Whether the
proposed collection of information is
necessary for the proper performance of
AHRQ healthcare research and
healthcare information dissemination
functions, including whether the
information will have practical utility;
(b) the accuracy of AHRQ’s estimate of
burden (including hours and costs) of
the proposed collection(s) of
information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information upon the
respondents, including the use of
automated collection techniques or
other forms of in formation technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
VerDate Mar<15>2010
15:35 Apr 30, 2010
Jkt 220001
comments will become a matter of
public record.
Government-Owned Inventions;
Availability for Licensing
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
Retroviral Vectors for Selective
Reversible Immortalization of
Stimulus-responding Primary Cells
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
Description of Invention: Researchers
at the National Cancer InstituteFrederick, NIH, have developed a novel
set of retroviral vectors and producer
cell lines useful for selective reversible
immortalization of primary cells (i.e.
lymphocytes) that respond to a
stimulus, such as a viral antigen (e.g.
Dated: April 20, 2010.
Carolyn M. Clancy,
Director.
[FR Doc. 2010–10195 Filed 4–30–10; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
E:\FR\FM\03MYN1.SGM
03MYN1
Federal Register / Vol. 75, No. 84 / Monday, May 3, 2010 / Notices
HIV toxoids), a tumor antigen, or a
growth factor.
Derived from the murine leukemia
virus (MuLV), these retroviral vectors
will only infect dividing cells.
Therefore, only primary cells activated
by the stimulus will be infected and
immortalized, thereby creating an
‘‘antigen-specific trap.’’
The primary cells to be immortalized
can be in targeted tissue or in stimulated
ex vivo culture. The transduced cells
can be expanded to large numbers
without differentiating, and returned to
the primary cell stage by removal of the
introduced genes using a vector excision
strategy.
Applications
• Isolation/replication of normally
short-lived primary cells that respond to
a stimulus.
• Immortalization of antigen-specific
T cells for vaccine development or
adoptive transfer immunotherapy.
• Production of primary cell lines for
large-scale production of cell-secreted
factors, cytokines, and other molecules.
erowe on DSK5CLS3C1PROD with NOTICES
Advantages
• System acts as an anti-senescence
treatment: Cells that are normally shortlived can be kept in culture for years.
• Vectors with different markers are
available to identify transduced cells
and for cell selection.
• Excision allows for gene/marker
removal.
• The MuLV-based system only
infects dividing (e.g. activated) cells
Inventors: Eugene V. Barsov and
David E. Ott (NCI).
Relevant Publications
1. E Barsov et al. Capture of antigenspecific T lymphocytes from human
blood by selective immortalization
to establish long-term T-cell lines
maintaining primary cell
characteristics. Immunol Lett. 2006
May 15;105(1):26–37. [PubMed:
16442639]
2. H Andersen et al. Transduction with
human telomerase reverse
transcriptase immortalizes a rhesus
macaque CD8+ T cell clone with
maintenance of surface marker
phenotype and function. AIDS Res
Hum Retroviruses 2007
Mar;23(3):456–465. [PubMed:
17411379]
Patent Status: HHS Reference No. E–
140–2010/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: Available for
biological materials licensing only.
Licensing Contact: Patrick P. McCue,
PhD; 301–435–5560;
mccuepat@mail.nih.gov.
VerDate Mar<15>2010
15:35 Apr 30, 2010
Jkt 220001
Collaborative Research Opportunity:
The Center for Cancer Research, AIDS
and Cancer Virus Program, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize this technology. Please
contact John Hewes, PhD at 301–435–
3131 or hewesj@mail.nih.gov. for more
information.
A Method of Measuring Ultraviolet A
(UVA) Protection in Sunscreen
Products
Description of Invention: There are
different types of ultraviolet (UV) rays
in sunlight. UVB radiation causes
redness (erythema) or sunburn. While
UVA radiation, which absorbs deep into
the skin, causes more long-term effects
such as wrinkles, skin aging and skin
cancer.
Effective sunscreens are expected to
block both UVA and UVB radiation. The
Sun Protection Factor (SPF) label found
on all over-the-counter sunscreen
products is a better measure for UVB
protection than UVA protection.
Currently, there is no standard in vivo
test to determine the amount of UVA
protection in sunscreen products,
despite the fact that many products are
advertised as effectively blocking both
UVA and UVB radiation.
This invention describes sets of genes
useful for measuring UVA exposure in
human skin and assessing sunscreen
products for their ability to block UVA
radiation.
Application: A test for measuring
UVA protection provided by
sunscreens.
Development Status: Early stage.
Market: According to a report by the
Global Industry Analysts, Inc., the sun
care market is projected to reach $5.6
billion by the year 2015.
Inventors: Atsushi Terunuma and
Jonathan C. Vogel (NCI).
Related Publication: In preparation.
Patent Status: U.S. Provisional
Application No. 61/309,179 filed 01 Mar
2010 (HHS Reference No. E–097–2010/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Charlene Sydnor,
PhD; 301–435–4689;
sydnorc@mail.nih.gov.
Collaborative Research Opportunity:
The Center for Cancer Research,
Dermatology Branch, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize this technology. Please
contact John Hewes, PhD at 301–435–
3131 or hewesj@mail.nih.gov for more
information.
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
23273
Laser Scanning Microscopy for Three
Dimensional Motion Tracking for
Volumetric Data
Description of Invention: The
technology offered for licensing and for
further development is in the field of
volumetric tissue scanning microscopy.
More specifically, the invention
provides for a device, system and
methods that can acquire and analyze
volumetric data from a high-speed laserscanning microscope and compute
motion of the sample under the
microscope in three dimensions. This
computed motion is used to adjust
position of the sample in real time to
maintain field of view and relative
location. This motion compensation
scheme can be used to collect micronscale information over time, which can
be important in a number of research or
medical device applications.
Applications
• Biomedical research involving in
vivo microscopy.
• Real time tracking of cells or
cellular structures.
• Tracking tissue during various
physiological perturbations and
observation of dynamic physiological
processes. Physiological perturbations
include metabolic substrates, drug
delivery and anoxia.
• Potential applications in molecular
diagnostic imaging.
• Potential applications in medical
procedures such as biopsy and
microsurgery where information has to
be collected from a specific microscope
location over a period of time.
Advantages
• Improved analytical capabilities for
biological processes.
• Improved capabilities of accurately
examining and studying physiological
perturbations.
• Potential improvement in medical
procedures such as biopsy.
• May readily be adaptable to
commercial microscopes.
Development Status: The invention is
fully developed. Further work needs to
be done in the following areas:
• Adaptation to different types of
microscopes.
• Further demonstration of utility of
in-vivo imaging.
Inventors: James L. Schroeder
(NHLBI) et al.
Related Publication: Schroeder JL,
Luger-Hamer M, Pursley R, Pohida T,
Chefd’Hotel C, Kellman P, Balaban RS.
Short communication: Subcellular
motion compensation for minimally
invasive microscopy, in vivo: evidence
for oxygen gradients in resting muscle.
E:\FR\FM\03MYN1.SGM
03MYN1
23274
Federal Register / Vol. 75, No. 84 / Monday, May 3, 2010 / Notices
Circ Res. 2010 Apr 2;106(6):1129–1133.
[PubMed: 20167928].
Patent Status: U.S. Provisional
Application No. 61/245,586 filed 24 Sep
2009 (HHS Reference No. E–290–2009/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contacts: Uri Reichman,
PhD, MBA; 301–435–4616;
UR7a@nih.gov, or Michael Shmilovich,
Esq.; 301–435–5019;
ShmilovichM@mail.nih.gov.
Collaborative Research Opportunity:
The National Heart, Lung, and Blood
Institute, Laboratory of Cardiac
Energetics, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize automatic 3D volumetric
motion tracking systems for use during
in vivo microscopy. Please contact
Denise Crooks, PhD at 301–435–0103 or
crooksd@nhlbi.nih.gov for more
information.
Dated: April 26, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–10264 Filed 4–30–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Office of the Secretary
[Docket No. DHS–2010–0031]
Privacy Act of 1974; Department of
Homeland Security United States
Immigration Customs and
Enforcement—011 Immigration and
Enforcement Operational Records
System of Records
Privacy Office, DHS.
Notice of amendment of Privacy
Act system of records.
AGENCY:
erowe on DSK5CLS3C1PROD with NOTICES
ACTION:
SUMMARY: In accordance with the
Privacy Act of 1974 the Department of
Homeland Security U.S. Immigration
and Customs Enforcement is updating
an existing system of records titled,
Department of Homeland Security/U.S.
Immigration and Customs
Enforcement—011 Immigration and
Enforcement Operational Records
System of Records (ENFORCE). With the
publication of this updated system of
records, a new routine use has been
proposed. The routine use would
support the deployment of the ICE
Online Detainee Locator System, which
provides a searchable online database to
VerDate Mar<15>2010
15:35 Apr 30, 2010
Jkt 220001
help members of the public locate
detainees in ICE custody. This routine
use would also support the sharing of
information about ICE detainees for the
purpose of allowing family members
and other individuals to deposit money
in detainee accounts for telephone and
commissary services within a detention
facility. A Privacy Impact Assessment
that describes the Online Detainee
Locator System is being published
concurrently with this notice. It can be
found on the DHS Web site at https://
www.dhs.gov/privacy. This updated
system will continue to be included in
the Department of Homeland Security’s
inventory of record systems.
DATES: Submit comments on or before
June 2, 2010. This amended system will
be effective June 2, 2010.
ADDRESSES: You may submit comments,
identified by docket number DHS–
2010–0031 by one of the following
methods:
• Federal e-Rulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Fax: 703–483–2999.
• Mail: Mary Ellen Callahan, Chief
Privacy Officer, Privacy Office,
Department of Homeland Security,
Washington, DC 20528.
• Instructions: All submissions
received must include the agency name
and docket number for this rulemaking.
All comments received will be posted
without change to https://
www.regulations.gov, including any
personal information provided.
• Docket: For access to the docket to
read background documents or
comments received go to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Lyn
Rahilly (703–732–3300), Privacy Officer,
U.S. Immigration and Customs
Enforcement, 500 12th Street, SW., Mail
Stop 5004, Washington, DC 20536; or
Mary Ellen Callahan (703–235–0780),
Chief Privacy Officer, Privacy Office,
U.S. Department of Homeland Security,
Washington, DC 20528.
SUPPLEMENTARY INFORMATION:
I. Background
ICE is proposing a new routine use to
permit sharing of limited information
about current and former persons in ICE
custody through the Online Detainee
Locator System (ODLS). ODLS is a
publicly accessible, Web-based system
owned by U.S. Immigration and
Customs Enforcement (ICE) Office of
Detention and Removal Operations
(DRO).
DRO is responsible for promoting
public safety and national security by
arresting, detaining, and removing
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
persons from the United States in
accordance with the Immigration and
Nationality Act. ICE developed ODLS as
a service to the public, especially family
members and legal representatives, to
help locate individuals arrested for
administrative immigration violations
and who are in or have recently left ICE
custody (‘‘detainees’’). Currently,
members of the public must contact a
DRO field office by phone to determine
the location of a detainee. With the
deployment of this automated system,
the public will be able to locate
detainees more quickly and efficiently
through an online query. The system
will ultimately be available in several
languages to help users whose native
language is not English.
ODLS is a Web-based system that is
accessible from an Internet browser and
may be used by any member of the
public. ODLS is scheduled to deploy in
June 2010, and will be accessible by
visiting ICE’s public Web site (https://
www.ice.gov/locator). Persons using
ODLS do not need to set up an account
or get special permission to use the
system. ODLS provides two ways to
search for a detainee: (1) Perform a
query using an Alien Registration
Number (A–Number) and country of
birth; or (2) perform a query using a full
name and country of birth. After
receiving the query entered by the user,
ODLS searches for a match among
current ICE detainees and detainees
who have been booked out of ICE
custody (regardless of the reason) within
the last 60 days. All records that match
the user’s query are returned to the user
in a list of one or more search results.
ODLS only performs exact-match
searches. This means that the search
query entered by the user (specifically,
the name or A–Number) must exactly
match the information in a detention
record in order for the record to be
identified as a match and included in
the ODLS search results. For example, a
search for ‘‘Robert Smith’’ will not return
a detention record for ‘‘Robert Smyth’’ or
‘‘Bob Smith.’’ When conducting an A–
Number search, ODLS users will see a
maximum of one record in the results
because A–Numbers are assigned to
individuals uniquely. When conducting
a name-based search, however, ODLS
users may see multiple records in the
results if several detainees share the
same name and country of birth. Users
may use the year of birth provided in
the results to distinguish among
detainees with the same name.
ODLS only contains information
about individuals who are currently in
ICE custody or were previously detained
by ICE within the past 60 days. If a
search is performed for detainees who
E:\FR\FM\03MYN1.SGM
03MYN1
]]>Agencies
[Federal Register Volume 75, Number 84 (Monday, May 3, 2010)]
[Notices]
[Pages 23272-23274]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-10264]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Retroviral Vectors for Selective Reversible Immortalization of
Stimulus-responding Primary Cells
Description of Invention: Researchers at the National Cancer
Institute-Frederick, NIH, have developed a novel set of retroviral
vectors and producer cell lines useful for selective reversible
immortalization of primary cells (i.e. lymphocytes) that respond to a
stimulus, such as a viral antigen (e.g.
[[Page 23273]]
HIV toxoids), a tumor antigen, or a growth factor.
Derived from the murine leukemia virus (MuLV), these retroviral
vectors will only infect dividing cells. Therefore, only primary cells
activated by the stimulus will be infected and immortalized, thereby
creating an ``antigen-specific trap.''
The primary cells to be immortalized can be in targeted tissue or
in stimulated ex vivo culture. The transduced cells can be expanded to
large numbers without differentiating, and returned to the primary cell
stage by removal of the introduced genes using a vector excision
strategy.
Applications
Isolation/replication of normally short-lived primary
cells that respond to a stimulus.
Immortalization of antigen-specific T cells for vaccine
development or adoptive transfer immunotherapy.
Production of primary cell lines for large-scale
production of cell-secreted factors, cytokines, and other molecules.
Advantages
System acts as an anti-senescence treatment: Cells that
are normally short-lived can be kept in culture for years.
Vectors with different markers are available to identify
transduced cells and for cell selection.
Excision allows for gene/marker removal.
The MuLV-based system only infects dividing (e.g.
activated) cells
Inventors: Eugene V. Barsov and David E. Ott (NCI).
Relevant Publications
1. E Barsov et al. Capture of antigen-specific T lymphocytes from human
blood by selective immortalization to establish long-term T-cell lines
maintaining primary cell characteristics. Immunol Lett. 2006 May
15;105(1):26-37. [PubMed: 16442639]
2. H Andersen et al. Transduction with human telomerase reverse
transcriptase immortalizes a rhesus macaque CD8+ T cell clone with
maintenance of surface marker phenotype and function. AIDS Res Hum
Retroviruses 2007 Mar;23(3):456-465. [PubMed: 17411379]
Patent Status: HHS Reference No. E-140-2010/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: Available for biological materials licensing
only.
Licensing Contact: Patrick P. McCue, PhD; 301-435-5560;
mccuepat@mail.nih.gov.
Collaborative Research Opportunity: The Center for Cancer Research,
AIDS and Cancer Virus Program, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. Please contact
John Hewes, PhD at 301-435-3131 or hewesj@mail.nih.gov. for more
information.
A Method of Measuring Ultraviolet A (UVA) Protection in Sunscreen
Products
Description of Invention: There are different types of ultraviolet
(UV) rays in sunlight. UVB radiation causes redness (erythema) or
sunburn. While UVA radiation, which absorbs deep into the skin, causes
more long-term effects such as wrinkles, skin aging and skin cancer.
Effective sunscreens are expected to block both UVA and UVB
radiation. The Sun Protection Factor (SPF) label found on all over-the-
counter sunscreen products is a better measure for UVB protection than
UVA protection. Currently, there is no standard in vivo test to
determine the amount of UVA protection in sunscreen products, despite
the fact that many products are advertised as effectively blocking both
UVA and UVB radiation.
This invention describes sets of genes useful for measuring UVA
exposure in human skin and assessing sunscreen products for their
ability to block UVA radiation.
Application: A test for measuring UVA protection provided by
sunscreens.
Development Status: Early stage.
Market: According to a report by the Global Industry Analysts,
Inc., the sun care market is projected to reach $5.6 billion by the
year 2015.
Inventors: Atsushi Terunuma and Jonathan C. Vogel (NCI).
Related Publication: In preparation.
Patent Status: U.S. Provisional Application No. 61/309,179 filed 01
Mar 2010 (HHS Reference No. E-097-2010/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Charlene Sydnor, PhD; 301-435-4689;
sydnorc@mail.nih.gov.
Collaborative Research Opportunity: The Center for Cancer Research,
Dermatology Branch, is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize this technology. Please contact John Hewes,
PhD at 301-435-3131 or hewesj@mail.nih.gov for more information.
Laser Scanning Microscopy for Three Dimensional Motion Tracking for
Volumetric Data
Description of Invention: The technology offered for licensing and
for further development is in the field of volumetric tissue scanning
microscopy. More specifically, the invention provides for a device,
system and methods that can acquire and analyze volumetric data from a
high-speed laser-scanning microscope and compute motion of the sample
under the microscope in three dimensions. This computed motion is used
to adjust position of the sample in real time to maintain field of view
and relative location. This motion compensation scheme can be used to
collect micron-scale information over time, which can be important in a
number of research or medical device applications.
Applications
Biomedical research involving in vivo microscopy.
Real time tracking of cells or cellular structures.
Tracking tissue during various physiological perturbations
and observation of dynamic physiological processes. Physiological
perturbations include metabolic substrates, drug delivery and anoxia.
Potential applications in molecular diagnostic imaging.
Potential applications in medical procedures such as
biopsy and microsurgery where information has to be collected from a
specific microscope location over a period of time.
Advantages
Improved analytical capabilities for biological processes.
Improved capabilities of accurately examining and studying
physiological perturbations.
Potential improvement in medical procedures such as
biopsy.
May readily be adaptable to commercial microscopes.
Development Status: The invention is fully developed. Further work
needs to be done in the following areas:
Adaptation to different types of microscopes.
Further demonstration of utility of in-vivo imaging.
Inventors: James L. Schroeder (NHLBI) et al.
Related Publication: Schroeder JL, Luger-Hamer M, Pursley R, Pohida
T, Chefd'Hotel C, Kellman P, Balaban RS. Short communication:
Subcellular motion compensation for minimally invasive microscopy, in
vivo: evidence for oxygen gradients in resting muscle.
[[Page 23274]]
Circ Res. 2010 Apr 2;106(6):1129-1133. [PubMed: 20167928].
Patent Status: U.S. Provisional Application No. 61/245,586 filed 24
Sep 2009 (HHS Reference No. E-290-2009/0-US-01).
Licensing Status: Available for licensing.
Licensing Contacts: Uri Reichman, PhD, MBA; 301-435-4616;
UR7a@nih.gov, or Michael Shmilovich, Esq.; 301-435-5019;
ShmilovichM@mail.nih.gov.
Collaborative Research Opportunity: The National Heart, Lung, and
Blood Institute, Laboratory of Cardiac Energetics, is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
automatic 3D volumetric motion tracking systems for use during in vivo
microscopy. Please contact Denise Crooks, PhD at 301-435-0103 or
crooksd@nhlbi.nih.gov for more information.
Dated: April 26, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-10264 Filed 4-30-10; 8:45 am]
BILLING CODE 4140-01-P
